Actively Recruiting
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Led by Qing Su · Updated on 2025-07-08
126
Participants Needed
1
Research Sites
94 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The ageing of our country is increasing and the ageing of the population has led to a significant increase in aging related diseases. During the aging process of the organism, cellular senescence can occur in all systems of the body, of which the senescence of the immune system is called immunosenescence. Some studies have shown that metabolic disorders can also trigger aging. This study investigated the effect of nicotinamide mononucleotide (NMN) supplementation on immunosenescence in middle-aged and elderly people through a placebo-controlled long-range clinical trail, aiming to provide a new method to improve immunosenescence. The effects of NMN supplementation on glucose and lipid metabolic indexes, body composition and telomere length of peripheral blood cells are also investigated, which may open up new ideas for the prevention and treatment of glucose and lipid metabolic diseases.
CONDITIONS
Official Title
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50 to 70 years with overweight or obesity (BMI 24 kg/m2 or higher)
- Diagnosis of at least one: metabolism-related fatty liver disease (ultrasound confirmed), pre-diabetes, or type 2 diabetes mellitus with HbA1c less than 7% without glucose-lowering drug treatment
- Ability to participate in the trial, adhere to follow-up, visit the hospital independently, and provide signed informed consent
You will not qualify if you...
- Diagnosis of tumors
- Presence of autoimmune diseases excluding Hashimoto's thyroiditis
- Severe cardiovascular disease or heart failure
- Systolic blood pressure over 160 mmHg or diastolic blood pressure over 100 mmHg
- Chronic obstructive pulmonary disease
- Chronic active hepatitis or cirrhosis
- Chronic kidney failure
- History of stroke
- Severe blood disorders
- Infectious diseases
- Mental illness
- Conditions that may affect study results as judged by the investigator
- Use of NMN or other anti-aging agents within the last six months
- Premenopausal women
- ALT or AST liver enzyme levels more than three times the normal upper limit
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China
Actively Recruiting
Research Team
S
Su
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here